Ph.D., Chief Scientific Officer, Affimed
Martin joined Affimed’s Management Team in 2015 as Chief Scientific Officer. He has a proven track record in preclinical and clinical biotherapeutic discovery, having established a broad research pipeline of programs in targeted cancer therapy and immuno-oncology. Martin has more than 15 years of professional experience. Prior to Affimed, Martin was co-founder and Chief Scientific Officer of CT Atlantic AG and co-founder of U3 Pharma AG. Martin graduated with Honors from Monash University in Melbourne, Australia and obtained a diploma in Biology at the University of Würzburg, Germany. He earned his PhD working in Prof. Axel Ullrich’s group at the Max Planck Institute of Biochemistry in Martinsried-Munich, Germany.
Presentation Title and Company Description
Immunotherapy Showcase: Harnessing Innate and Adaptive Immunity to Treat Cancer
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases.